Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment is a research paper published in Cancer Letters (2024). On theSindex it has a DataRank of 0.607. It has been cited 16 times, with 12 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0.182
From 8 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 12 citers.